Omeprazole and losartan
Pro Research Analysisby 
Searched over 200M research papers
Drug-Drug Interactions and Pharmacokinetics of Omeprazole and Losartan
Introduction to Omeprazole and Losartan
Omeprazole and losartan are commonly prescribed medications with distinct therapeutic uses. Omeprazole is a proton pump inhibitor (PPI) used to treat gastroesophageal reflux disease (GERD) and other acid-related stomach issues, while losartan is an angiotensin II receptor blocker (ARB) used primarily for managing hypertension and protecting the kidneys in diabetic patients. Understanding their pharmacokinetics and potential drug-drug interactions is crucial for optimizing therapeutic outcomes and minimizing adverse effects.
Pharmacokinetics and Drug-Drug Interactions
Omeprazole and Losartan with Sucroferric Oxyhydroxide
A study investigated the potential pharmacokinetic interactions between sucroferric oxyhydroxide, an iron-based phosphate binder, and several drugs including omeprazole and losartan. The results indicated that the systemic exposure of both omeprazole and losartan was not significantly affected by the presence of sucroferric oxyhydroxide, suggesting a low risk of clinically significant drug-drug interactions when these medications are co-administered .
Cytochrome P450 Enzyme Phenotyping
Several studies have utilized cocktail approaches to phenotype cytochrome P450 (CYP) enzymes, which are crucial for drug metabolism. The Karolinska cocktail and the Inje cocktail, which include omeprazole and losartan as probe drugs, have been used to assess the activity of CYP2C19 and CYP2C9, respectively. These studies confirmed that the cocktails could be administered simultaneously without significant pharmacokinetic interactions, making them effective tools for evaluating CYP enzyme activity Christensen2003Ryu2007Williams2016.
Impact of Disease States on Drug Metabolism
Research has shown that disease states can significantly alter drug metabolism. For instance, in patients with visceral leishmaniasis, the activities of CYP3A4 and CYP2C19 were significantly reduced during the acute phase of the disease, which could affect the metabolism of drugs like omeprazole and losartan. This reduction in enzyme activity was attributed to increased levels of proinflammatory cytokines during active disease .
Pediatric Considerations
In pediatric patients with nonalcoholic steatohepatitis (NASH), the activity of CYP2C19 was significantly decreased, affecting the metabolism of omeprazole. This suggests that NASH can be a confounder in drug metabolism, necessitating careful consideration of dosage adjustments in this population .
Herbal-Drug Interactions
A study on the potential interactions between a standardized propolis extract (EPP-AF®) and various drugs, including omeprazole and losartan, found that while there were statistically significant changes in the pharmacokinetics of these drugs, the magnitude of these changes was below 20%. This indicates that propolis does not significantly alter the activities of CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A, and is likely safe regarding potential interactions .
Conclusion
The pharmacokinetics of omeprazole and losartan are influenced by various factors, including co-administered drugs, disease states, and patient demographics. Studies indicate that while there are some interactions, they are generally not clinically significant, allowing for the concomitant use of these medications with others like sucroferric oxyhydroxide and propolis extract. However, special considerations are necessary for populations with altered CYP enzyme activity, such as patients with visceral leishmaniasis or pediatric patients with NASH. Understanding these interactions helps in optimizing therapeutic regimens and ensuring patient safety.
Sources and full results
Most relevant research papers on this topic
The karolinska cocktail for phenotyping of five human cytochrome P450 enzymes
The karolinska cocktail, consisting of caffeine, losartan, omeprazole, debrisoquin, and quinine, can be administered in low doses for phenotyping CYP enzymes, with a schedule designed to minimize sampling opportunities.
Impact of visceral leishmaniasis and curative chemotherapy on cytochrome P450 activity in Brazilian patients.
Acute visceral leishmaniasis reduces CYP3A4 and CYP2C19 activity, possibly due to increased proinflammatory cytokines, while CYP2C9 activity remains unchanged.
Can the CEIBA Cocktail Designed for Human Cytochrome P450 Enzymes be Used in the Rat for Drug Interaction Studies?
The CEIBA cocktail is a useful tool for investigating drug interactions involving CYP isoenzymes in rats, particularly at the level of CYP1A2, CYP2D1/2, and CYP2D2 isoforms.
DOI